ArticleFrontiers in oncology2025
Prediction of bone oligometastases in breast cancer using models based on deep learning radiomics of PET/CT imaging.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Artificial intelligence-assisted early screening of lung cancer and accurate diagnosis of pulmonary nodules: research progress and clinical prospects from radiomics to multi-omics integration: a narrative review.Journal of thoracic disease · 2026Review
- Leveraging the non-contrast CT component of PET/CT: an AI-driven delta-radiomics approach to monitor treatment response in metastatic breast cancer.BMC medical imaging · 2026Article
- Intelligent identification of osteoporosis on hip X-rays using vision transformer.Bone reports · 2026Article
- Radiomics and Deep Learning: Bridging Breast Cancer Imaging Phenotypes and Genomic Heterogeneity.Breast cancer (Dove Medical Press) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop a deep learning radiomics(DLR)model integrating PET/CT radiomics, deep learning features, and clinical parameters for early prediction of bone oligometastases (≤5 lesions) in breast cancer. Methods: We retrospectively analyzed 207 breast cancer patients with 312 bone lesions, comprising 107 benign and 205 malignant lesions, including 89 lesions with confirmed bone metastases. Radiomic features were extracted from computed tomography (CT), positron emission tomography (PET), and fused PET/CT images using PyRadiomics embedded in the uAI Research Portal. Standardized feature extraction and feature selection were performed using the Least Absolute Shrinkage and Selection Operator (LASSO) method. We developed and validated three models: a radiomics-based model, a deep learning model using BasicNet, and a deep learning radiomics (DLR) model incorporating clinical and metabolic parameters. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity. Statistical comparisons were conducted using the DeLong test. Results: Visual assessment of fused PET/CT images identified 227 (72.8%) abnormal lesions, demonstrating greater sensitivity than CT or PET alone. The complex radiomics model achieved a sensitivity of 98.9% [96.1%-99.4%], specificity of 98.2% [88.1%-99.6%], accuracy of 98.7% [89.6%-99.5%], and area under the curve (AUC) of 0.989. The BasicNet model outperformed other transfer learning models, achieving an AUC of 0.961. The DeLong test confirmed that the AUC of the BasicNet model was significantly higher than the traditional radiomics model. The DLR+Complex model with a random forest classifier achieved the highest overall performance, with an AUC of 0.990, sensitivity of 98.6%, specificity of 90.5%, and accuracy of 99.8%. Conclusions: The BasicNet model significantly outperformed traditional radiomics approaches in predicting bone oligometastases in breast cancer patients. The DLR+Complex model demonstrated the best predictive performance across all metrics. Future strategies for precise diagnosis and treatment should incorporate histologic subtype, advanced imaging, and molecular biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.